VERONA PHARMA ($VRNA) is expected to release its quarterly earnings data on Monday, January 5th after market close, per Finnhub. Analysts are expecting revenue of $130,790,826 and earnings of $0.19 per share.
You can see Quiver Quantitative's $VRNA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
VERONA PHARMA Insider Trading Activity
VERONA PHARMA insiders have traded $VRNA stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $VRNA stock by insiders over the last 6 months:
- MARK W HAHN (Chief Financial Officer) sold 208,912 shares for an estimated $2,745,876
- DAVID ZACCARDELLI (President and CEO) sold 208,912 shares for an estimated $2,745,876
- KATHLEEN A. RICKARD (Chief Medical Officer) sold 58,336 shares for an estimated $766,750
- MICHAEL AUSTWICK sold 11,288 shares for an estimated $148,366
- MARTIN EDWARDS sold 10,808 shares for an estimated $142,057
- KENNETH CUNNINGHAM sold 10,808 shares for an estimated $142,057
- ANDREW FISHER (General Counsel) sold 9,584 shares for an estimated $125,969
- LISA DESCHAMPS sold 9,464 shares for an estimated $124,391
- VIKAS SINHA sold 4,328 shares for an estimated $56,885
- MAHENDRA SHAH sold 3,608 shares for an estimated $47,422
- DAVID R EBSWORTH sold 1,904 shares for an estimated $25,025
- CHRISTINA ACKERMANN sold 1,808 shares for an estimated $23,763
- JAMES ALOYSIUS BRADY sold 824 shares for an estimated $10,830
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
VERONA PHARMA Hedge Fund Activity
We have seen 140 institutional investors add shares of VERONA PHARMA stock to their portfolio, and 211 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PENTWATER CAPITAL MANAGEMENT LP added 5,300,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $565,563,000
- JANUS HENDERSON GROUP PLC removed 5,123,841 shares (-83.5%) from their portfolio in Q3 2025, for an estimated $546,765,073
- PERCEPTIVE ADVISORS LLC removed 4,983,503 shares (-90.5%) from their portfolio in Q3 2025, for an estimated $531,789,605
- HBK INVESTMENTS L P added 4,263,576 shares (+inf%) to their portfolio in Q3 2025, for an estimated $454,966,194
- DARWIN GLOBAL MANAGEMENT, LTD. removed 4,129,618 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $440,671,536
- FIL LTD added 3,488,500 shares (+inf%) to their portfolio in Q3 2025, for an estimated $372,257,835
- BLACKROCK, INC. added 3,483,014 shares (+1013.4%) to their portfolio in Q3 2025, for an estimated $371,672,423
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
VERONA PHARMA Analyst Ratings
Wall Street analysts have issued reports on $VRNA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Cantor Fitzgerald issued a "Overweight" rating on 10/08/2025
To track analyst ratings and price targets for VERONA PHARMA, check out Quiver Quantitative's $VRNA forecast page.
VERONA PHARMA Price Targets
Multiple analysts have issued price targets for $VRNA recently. We have seen 5 analysts offer price targets for $VRNA in the last 6 months, with a median target of $107.0.
Here are some recent targets:
- Olivia Brayer from Cantor Fitzgerald set a target price of $100.0 on 10/08/2025
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $107.0 on 07/14/2025
- Tiago Fauth from Wells Fargo set a target price of $107.0 on 07/10/2025
- Suji Jeong from Jefferies set a target price of $107.0 on 07/09/2025
- Edward Nash from Canaccord Genuity set a target price of $107.0 on 07/09/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
